These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 9716204)

  • 1. Vasoseal hemostasis following coronary interventions with Abciximab.
    Lunney L; Karim K; Little T
    Cathet Cardiovasc Diagn; 1998 Aug; 44(4):405-6. PubMed ID: 9716204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasoseal hemostasis following coronary interventions with abciximab.
    Lunney L; Karim K; Little T
    J Invasive Cardiol; 1999 Sep; 11 Suppl B():2B-3B. PubMed ID: 10745610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of vascular sealing devices (VasoSeal and Perclose) versus assisted manual compression (Femostop) in transcatheter coronary interventions requiring abciximab (ReoPro).
    Chamberlin JR; Lardi AB; McKeever LS; Wang MH; Ramadurai G; Grunenwald P; Towne WP; Grassman ED; Leya FS; Lewis BE; Stein LH
    Catheter Cardiovasc Interv; 1999 Jun; 47(2):143-7; discussion 148. PubMed ID: 10376492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators.
    Lincoff AM; Tcheng JE; Califf RM; Bass T; Popma JJ; Teirstein PS; Kleiman NS; Hattel LJ; Anderson HV; Ferguson JJ; Cabot CF; Anderson KM; Berdan LG; Musco MH; Weisman HF; Topol EJ
    Am J Cardiol; 1997 Feb; 79(3):286-91. PubMed ID: 9036746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long term efficacy of abciximab bolus-only compared to abciximab bolus and infusion after transradial coronary stenting.
    Bagur R; Bertrand OF; Rodés-Cabau J; Larose E; Rinfret S; Nguyen CM; Noel B; Larochellière RD; Poirier P; Costerousse O; Roy L
    Catheter Cardiovasc Interv; 2009 Dec; 74(7):1010-6. PubMed ID: 19753635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of abciximab use in conjunction with intracoronary urokinase in patients requiring angioplasty.
    Rashdan I; Schechter E
    Catheter Cardiovasc Interv; 2000 Jan; 49(1):113-6. PubMed ID: 10627383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abciximab readministration: results of the ReoPro Readministration Registry.
    Tcheng JE; Kereiakes DJ; Lincoff AM; George BS; Kleiman NS; Sane DC; Cines DB; Jordan RE; Mascelli MA; Langrall MA; Damaraju L; Schantz A; Effron MB; Braden GA
    Circulation; 2001 Aug; 104(8):870-5. PubMed ID: 11514371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective randomized trial comparing the safety and efficacy of three commercially available closure devices (Angioseal, Vasoseal and Duett).
    Michalis LK; Rees MR; Patsouras D; Katsouras CS; Goudevenos J; Pappas S; Sourla E; Kolettis T; Sioros L; Zotou P; Gartzou-Matsouka P; Sideris DA
    Cardiovasc Intervent Radiol; 2002; 25(5):423-9. PubMed ID: 12132030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abciximab as an adjunct to high-risk carotid or vertebrobasilar angioplasty: preliminary experience.
    Qureshi AI; Suri MF; Khan J; Fessler RD; Guterman LR; Hopkins LN
    Neurosurgery; 2000 Jun; 46(6):1316-24; discussion 1324-5. PubMed ID: 10834637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab.
    Mascelli MA; Kleiman NS; Marciniak SJ; Damaraju L; Weisman HF; Jordan RE
    Am Heart J; 2000 Apr; 139(4):696-703. PubMed ID: 10740154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group.
    Berkowitz SD; Sane DC; Sigmon KN; Shavender JH; Harrington RA; Tcheng JE; Topol EJ; Califf RM
    J Am Coll Cardiol; 1998 Aug; 32(2):311-9. PubMed ID: 9708455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Gastrointestinal bleeding in a patient with acute myocardial infarction treated with primary coronary angioplasty and abciximab (ReoPro) administration].
    Gziut AI; Pastwa Ł; Słysz A
    Kardiol Pol; 2006 Mar; 64(3):334-6; discussion 337-8. PubMed ID: 16583343
    [No Abstract]   [Full Text] [Related]  

  • 13. Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study.
    van den Merkhof LF; Zijlstra F; Olsson H; Grip L; Veen G; Bär FW; van den Brand MJ; Simoons ML; Verheugt FW
    J Am Coll Cardiol; 1999 May; 33(6):1528-32. PubMed ID: 10334418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized study comparing same-day home discharge and abciximab bolus only to overnight hospitalization and abciximab bolus and infusion after transradial coronary stent implantation.
    Bertrand OF; De Larochellière R; Rodés-Cabau J; Proulx G; Gleeton O; Nguyen CM; Déry JP; Barbeau G; Noël B; Larose E; Poirier P; Roy L;
    Circulation; 2006 Dec; 114(24):2636-43. PubMed ID: 17145988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe delayed thrombocytopenia associated with abciximab (ReoPro) therapy.
    Reddy MS; Carmody TJ; Kereiakes DJ
    Catheter Cardiovasc Interv; 2001 Apr; 52(4):486-8. PubMed ID: 11285605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: implications for a potential anticoagulant effect of abciximab.
    Dangas G; Badimon JJ; Coller BS; Fallon JT; Sharma SK; Hayes RM; Meraj P; Ambrose JA; Marmur JD
    Arterioscler Thromb Vasc Biol; 1998 Aug; 18(8):1342-9. PubMed ID: 9714143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of abciximab on the pattern of reperfusion in patients with acute myocardial infarction treated with primary angioplasty. RAPPORT investigators. ReoPro And Primary PTCA Organization and Randomized Trial.
    Brener SJ; Barr LA; Burchenal JE; Wolski KE; Effron MB; Topol EJ
    Am J Cardiol; 1999 Sep; 84(6):728-30, A8. PubMed ID: 10498145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute profound thrombocytopenia following abciximab therapy.
    Bishara AI; Hagmeyer KO
    Ann Pharmacother; 2000; 34(7-8):924-30. PubMed ID: 10928405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bleeding risks with abciximab after full-dose thrombolysis in rescue or urgent angioplasty for acute myocardial infarction.
    Jong P; Cohen EA; Batchelor W; Lazzam C; Kreatsoulas C; Natarajan MK; Strauss BH
    Am Heart J; 2001 Feb; 141(2):218-25. PubMed ID: 11174335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bleeding complications of platelet glycoprotein IIb/IIIa inhibitor abciximab (ReoPro ).
    Trivedi SM; Shani J; Hollander G
    J Invasive Cardiol; 2002 Jul; 14(7):423-5. PubMed ID: 12082199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.